Approaching a New Age in Duchenne Muscular Dystrophy Treatment

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 583-591

  Wagner, Kathryn R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trials; Duchenne; gene therapy; muscular dystrophy; myostatin; therapeutics

Indexed keywords

2 O METHYL PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BIGLYCAN; BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; GENTAMICIN; I KAPPA B; LOSARTAN; MYO 029; MYOSTATIN INHIBITOR; NEUTRALIZING ANTIBODY; OLIGOMER; PARVOVIRUS VECTOR; PENTOXIFYLLINE; PERINDOPRIL; PREDNISONE; PTC 124; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; BECKER MUSCULAR DYSTROPHY; BEHAVIOR DISORDER; BONE DISEASE; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DUCHENNE MUSCULAR DYSTROPHY; HEART AFTERLOAD; HUMAN; INFLAMMATION; MUSCLE GROWTH; MUSCLE REGENERATION; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CARE; RESPIRATORY FAILURE; SIDE EFFECT; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DYSTROPHIN; GENE THERAPY; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; REGENERATION;

EID: 53049083626     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.013     Document Type: Article

References (105)

1. Moxley III R.T., Ashwal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society 64 (2005) 13-20
2. Fitch K., Bernstein S.J., Aguilar M.S., et al. The RAND/UCLA Appropriateness Method User's Manual (2001), RAND Corp, Santa Monica, CA
3. Griggs R.C., Moxley III R.T., Mendell J.R., et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 48 (1991) 383-388
4. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. New Engl J Med 320 (1989) 1592-1597
5. Manzur A.Y., Kukntzer T., Pike M., and Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Review). The Cochrane Library (2006) 1-41
6. Alman B.A., Raza S.N., and Biggar W.D. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg Am 86-A (2004) 519-524
7. Biggar W.D., Harris V.A., Eliasoph L., and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Disord 16 (2006) 249-255
8. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68 (2007) 1607-1613
9. Pandya S., Guntrum D., and Moxley R.T. Long term daily prednisone therapy delays decline in pulmonary function and improves survival in patients with Duchenne dystrophy. Neuromusc Disord 15 (2005) 687
10. Wagner K.R., Lechtzin N., and Judge D.P. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 1772 (2007) 229-237
11. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromusc Disord 12 (2002) 912-925
12. Fenichel G.M., Mendell J.R., Moxley R.T., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991) 575-579
13. Kinali M., Mercuri E., Main M., and Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromusc Disord 12 suppl 1 (2002) S169-S174
14. Angelini C., Pegoraro E., Turella E., et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 17 (1994) 386-391
15. Biggar W.D., Gingras M., Fehlings D.L., et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138 (2001) 45-50
16. Bonifati M.D., Ruzza G., Bonometto P., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23 (2000) 1344-1347
17. Eagle M., Baudouin S., Chandler C., et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Disord 12 (2002) 926-929
18. Mohr C.H., and Hill N.S. Long-term follow-up of nocturnal ventilatory assistance in patients with respiratory failure due to Duchenne-type muscular dystrophy. Chest 97 (1990) 91-96
19. Simonds A.K., Muntoni F., Heather S., and Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53 (1998) 949-952
20. Balaban B., Matthews D.J., Clayton G.H., and Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 84 (2005) 843-850
21. Daftary A.S., Crisanti M., Kalra M., et al. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 119 (2007) e320-e324
22. Nigro G., Comi L.I., Politano L., and Bain R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26 (1990) 271-277
23. Markham L.W., Kinnett K., Wong B.L., et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc Disord 18 (2008) 365-370
24. Duboc D., Meune C., Lerebours G., et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45 (2005) 855-857
25. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. New Engl J Med 316 (1987) 1429-1435
26. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Engl J Med 325 (1991) 293-302
27. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
28. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
29. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
30. Griggs R.C., Moxley R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43 (1993) 520-527
31. Kissel J.T., Lynn D.J., Rammohan K.W., et al. Mononuclear cell analysis of muscle biopsies in prednisone and azathrioprine treated Duchenne muscular dystrophy. Neurology 43 (1993) 532-536
32. Fisher I., Abraham D., Bouri K., et al. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 19 (2005) 834-836
33. Hoffman E.P., Brown R.H., and Kunkel L.M. Dystrophin: the protein product of the duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
34. Odom G.L., Gregorevic P., and Chamberlain J.S. Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances. Biochim Biophys Acta 1772 (2007) 243-262
35. Rando T.A. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges. Biochim Biophys Acta 1772 (2007) 263-271
36. Crawford G.E., Faulkner J.A., Crosbie R.H., et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 150 (2000) 1399-1410
37. Fabb S.A., Wells D.J., Serpente P., and Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micodystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 11 (2002) 733-741
38. Liu M., Yue Y., Harper S.Q., et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11 (2005) 245-256
39. Sakamoto M., Yuasa K., Yoshimura M., et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 293 (2002) 1265-1272
40. Wang B., Li J., and Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 95 (2000) 10158-10163
41. Duan D., Yan Z., and Engelhardt J.F. Expanding the capacity of AAV vectors (2006), Hodder Arnold; Distributed in the USA by Oxford University Press, London, New York 525-532
42. Ghosh A., Yue Y., Lai Y., and Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 16 (2007) 124-130
43. Salva M.Z., Himeda C.L., Tai P.W.L., et al. Design of tissue-specific regulatory cassettes for high-level raav-mediated expression in skeletal and cardiac muscle. Mol Ther 15 (2007) 320-329
44. Bremmer-Bout M., Aartsma-Rus A., de Meijer E.J., et al. Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10 (2004) 232-240
45. Denti M.A., Rosa A., D'Antona G., et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci U S A 103 (2006) 3758-3763
46. Lu Q.L., Rabinowitz A., Chen Y.C., et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102 (2005) 198-203
47. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl J Med 357 (2007) 2677-2686
48. Barton-Davis E.R., Cordier L., Shoturma D.I., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104 (1999) 375-381
49. Dunant P., Walter M.C., Karpati G., and Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27 (2003) 624-627
50. Wagner K.R., Hamed S., Hadley D.W., et al. Gentamicin treatment of Duchenne and Becker Muscular Dystrophy due to nonsense mutations. Ann Neurol 49 (2001) 706-711
51. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
52. Hirawat S., Welch E.M., Elfring G.L., et al. Safety, tolerability and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47 (2007) 430-444
53. Engert J.C., Berglund E.B., and Rosenthal N. Proliferation precedes differentiation in IGF-1 stimulated myogenesis. J Cell Biol 135 (1996) 431-440
54. Rosenthal S.M., and Cheng Z.Q. Opposing early and late effects of insulin-like growth factor 1 on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci U S A 92 (1995) 10307-10311
55. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell B 37 (2005) 1974-1984
56. Barton E.R., Morris L., Musaro A., et al. Muscle-specific expression of insulin-like growth factor 1 counters muscle decline in mdx mice. J Cell Biol 157 (2002) 137-147
57. Shavlakadze T., White J., Hoh J.F.Y., et al. Targeted expression of insulin-like growth factor-1 reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther 10 (2004) 829-843
58. Gregorevic P., Plant D.R., Leeding K.R., et al. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-1 administration. Am J Pathology 161 (2002) 2263-2271
59. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997) 83-90
60. Lee S.-J. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 23 (2007) 475-477
61. Schuelke M., Wagner K.R., Stolz L.E., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. New Engl J Med 350 (2004) 2682-2688
62. Wagner K.R., McPherron A.C., Winik N., and Lee S.J. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52 (2002) 832-836
63. McCroskery S., Thomas M., Platt L., et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118 (2005) 3531-3541
64. Wagner K.R., Liu X., Chang X., and Allen R.E. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A 102 (2005) 2519-2524
65. McCroskery S., Thomas M., Maxwell L., et al. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 162 (2003) 1135-1147
66. Rios R., Carneiro I., Arce V.M., and Devesa J. Myostatin is an inhibitor of myogenic differentiation. Am J Physiol Cell Physiol 282 (2002) C993-C999
67. Taylor W.E., Bhasin S., Artaza J., et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 280 (2001) E221-E228
68. Thomas M., Langley B., Berry C., et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275 (2000) 40235-40243
69. Wagner K.R. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol 17 (2005) 720-724
70. Li Z.B., Kollias H.D., and Wagner K.R. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem (2008) M802585200
71. Zhu J., Li Y., Shen W., et al. Relationship between TGF-beta1, myostatin and decorin: implications for skeletal muscle fibrosis. J Biol Chem 282 (2007) 25852-25863
72. Lee S.J. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20 (2004) 61-86
73. Lee S.J., Reed L.A., Davies M.V., et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 102 (2005) 18117-18122
74. Bogdanovich S., Krag T.O., Barton E.R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
75. Qiao C., Li J., Jiang J., et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19 (2008) 241-254
76. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63 (2008) 561-571
77. Allen R.E., and Boxhorn L.K. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J Cell Physiol 1987 (1987) 576-572
78. Li Y., Foster W., Deasy B.M., et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathology 164 (2004) 1007-1019
79. Olson E.N., Sternberg E., Hu J.S., et al. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 103 (1986) 1799-1805
80. Bernasconi P., Torchiana E., Confalonieri P., et al. Expression of transforming growth factor-beta1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest 96 (1995) 1137-1144
81. Chen Y.W., Nagaraju K., Bakay M., et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65 (2005) 826-834
82. Zanotti S., Negri T., Cappelletti C., et al. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128 (2005) 2546-2555
83. Cohn R.D., van Erp C., Habashi J.P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13 (2007) 204-210
84. Lavoie P., Robitaille G., Agharazii M., et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertension 23 (2005) 1895-1903
85. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001) 789-791
86. Hayden M.S., and Ghosh S. Shared principles in NF-kB signaling. Cell 132 (2008) 344-362
87. Mourkioti F., and Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med 86 (2008) 747-759
88. Acharyya S., Villalta S.A., Bakkar N., et al. Interplay of IKK/NK-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117 (2007) 889-901
89. Monici M.C., Aguennouz M., Mazzeo A., et al. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60 (2003) 993-997
90. Porter J.D., Khanna S., Kaminski H.J., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11 (2002) 263-272
91. Tesi-Rocha C., Kuntz N., Clemens P.R., et al. Immediate release oral pentoxifylline is poorly tolerated in Duchenne muscular dystrophy boys. Neurology 70 suppl 1 (2008) A79
92. Escolar D., Gorni K., Tesi-Rocha A., et al. Pentoxifylline treatment fails to rescue muscle strength and function deterioration in prednisone-treated Duchenne muscular dystrophy. Neurology 70 suppl 1 (2008) A79
93. Burkin D.J., Wallace G.Q., Nicol K.J., et al. Enhanced expression of the alpha7-beta1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 152 (2001) 1207-1218
94. Nguyen H.H., Jayasinha V., Xia B., et al. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A 99 (2002) 5616-5621
95. Hildebrand A., Romaris M., Rasmussen L.M., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and firbomodulin with transforming growth factor beta. Biochem J 302 Part 2 (1994) 527-534
96. Rafii M.S., Hagiwara H., Mercado M.L., et al. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol 209 (2006) 439-447
97. Wiberg C., Hedbom E., Khairullina A., et al. Biglycan and deocrin bind close to the n-terminal region of the collagen VI triple helix. J Biol Chem 276 (2001) 18947-18952
98. Casar J.C., McKechnie B.A., Fallon J.R., et al. Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice. Dev Biol 268 (2004) 358-371
99. Mercado M.L., Amenta A.R., Hagiwara H., et al. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20 (2006) 1724-1726
100. Bulfield G., Siller W.G., Wight P.A., and Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81 (1984) 1189-1192
101. Dubowitz V. Therapeutic efforts in Duchenne muscular dystrophy: the need for a common language between basic scientists and clinicians. Neuromusc Disord 14 (2004) 451-455
102. Sharp N.J., Kornegay J.N., Van Camp S.D., et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13 (1992) 115-121
103. Cooper B.J., Winand N.J., Stedman H., et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334 (1988) 154-156
104. Valentine B.A., Winand N.J., Pradhan D., et al. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am J Med Genet 42 (1992) 352-356
105. Wagner J. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 48 (2008) 631-651